Argenx Takes Slow But Steady Approach To Vyvgart Sales

Amid Pandemic-Related And Educational Blocks

 
• By Ayisha Sharma

Despite a US approval for its novel FcRn inhibitor Vyvgart in gMG, the firm has realistic expectations of sales, factoring in concerns about COVID-19 and lagging medical education.  

Blocks with shopping trolleys representing sales
Vyvgart Sales May Not Be As High As Rival Soliris Off The Bat • Source: Alamy

More from Business

More from Scrip